Hypertrophic cardiomyopathy (HCM)

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder with an autosomal dominant pattern of inheritance that is characterized by hypertrophy of the left ventricles with histological features of myocyte hypertrophy, myfibrillar disarray, and interstitial fibrosis. HCM is one of the most common inherited cardiac disorders, with a prevalence in young adults of 1 in 500. Hundreds of mutations in the genes that encode protein constituents of the sarcomere have been identified in HCM. These mutations increase the Ca2+ sensitivity of cardiac myofilaments. Increased myofilament Ca2+ sensitivity is expected to increase the ATP utilization by actomyosin at submaximal Ca2+ concentrations, which might cause an imbalance in energy supply and demand in the heart under severe stress. The inefficient use of ATP suggests that an inability to maintain normal ATP levels could be the central abnormality. This theory might be supported by the discovery of the role of a mutant PRKAG2 gene in HCM, which in active form acts as a central sensing mechanism protecting cells from depletion of ATP supplies. The increase in the myfilament Ca2+ sensitivity well account for the diastolic dysfunction of model animals as well as human patients of HCM. It has been widely proposed that left ventricular hypertrophy is not a primary manifestation but develops as compensatory response to sarcomere dysfunction.

Human Diseases; Cardiovascular diseases

PMID:12270949

Fatkin D, Graham RM

Molecular mechanisms of inherited cardiomyopathies.

Physiol Rev 82:945-80 (2002)

PMID:12844200

Moolman-Smook JC, Mayosi BM, Brink PA, Corfield VA

Molecular genetics of cardiomyopathy: changing times, shifting paradigms.

Cardiovasc J S Afr 14:145-55 (2003)

PMID:14711353

Taylor MR, Carniel E, Mestroni L

Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing.

Expert Rev Mol Diagn 4:99-113 (2004)

Tei C (ed).

[Up to date of basic and clinical aspects of cardiomyopathies] (In Japanese)

Ishiyakushupan (2009)

PMID:10615904

Marian AJ

Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy.

Lancet 355:58-60 (2000)

PMID:11371514

Blair E, Redwood C, Ashrafian H, Oliveira M, Broxholme J, Kerr B, Salmon A, Ostman-Smith I, Watkins H

Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis.

Hum Mol Genet 10:1215-20 (2001)

PMID:11716909

Franz WM, Muller OJ, Katus HA

Cardiomyopathies: from genetics to the prospect of treatment.

Lancet 358:1627-37 (2001)

PMID:18056765

Morimoto S

Sarcomeric proteins and inherited cardiomyopathies.

Cardiovasc Res 77:659-66 (2008)

PMID:19136482

Cambronero F, Marin F, Roldan V, Hernandez-Romero D, Valdes M, Lip GY

Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis.

Eur Heart J 30:139-51 (2009)

PMID:11805847

Towbin JA, Bowles NE

The failing heart.

Nature 415:227-33 (2002)

PMID:11225594

Sorajja P, Elliott PM, McKenna WJ

The molecular genetics of hypertrophic cardiomyopathy: prognostic implications.

Europace 2:4-14 (2000)

PMID:18572189

Landstrom AP, Parvatiyar MS, Pinto JR, Marquardt ML, Bos JM, Tester DJ, Ommen SR, Potter JD, Ackerman MJ

Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C.

J Mol Cell Cardiol 45:281-8 (2008)